# TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

> **NCT02414945** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 9 (actual)

## Conditions studied

- Pleural Mesothelioma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Autologous tumor infiltrating lymphocytes (TILs)
- **BIOLOGICAL:** Interleukin-2

## Key facts

- **NCT ID:** NCT02414945
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-15
- **Primary completion:** 2020-10
- **Final completion:** 2020-10
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2023-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02414945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02414945, "TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02414945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*